ripretinib

ripretinib Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Ripretinib In Patients With Advanced Gastrointestinal Stromal Tumors WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 12, 2020– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced